sativex Report issue

Botanical Experimental
AACT Drug Central MeSH PubChem

Active Ingredient History

NOW
  • Now
Nabiximols is a specific Cannabis extract that was approved in 2010 as a botanical drug in the United Kingdom. Nabiximols is sold as a mouth spray intended to alleviate neuropathic pain, spasticity, overactive bladder, and other symptoms of multiple sclerosis; it was developed by the UK company GW Pharmaceuticals. In 2019 it was proposed that following application of the spray, nabiximols is washed away from the oral mucosa by the saliva flow and ingested into the stomach, with subsequent absorption from the gastro-intestinal tract. Nabiximols is a combination drug standardized in composition, formulation, and dose. Its principal active cannabinoid components are the cannabinoids: tetrahydrocannabinol (THC) and cannabidiol (CBD). Each spray delivers a dose of 2.7 mg THC and 2.5 mg CBD.   Wikipedia

Chemistry

  • SMILES: CCCCCc1cc(O)c([C@@H]2C=C(C)CC[C@H]2C(=C)C)c(O)c1.CCCCCc3cc(O)c4[C@@H]5C=C(C)CC[C@H]5C(C)(C)Oc4c3
  • InChIKey: SSNHGLKFJISNTR-DYSNNVSPSA-N
  • Mol. Mass: 628.94
  • ALogP: Missing data
  • ChEMBL Molecule:
    nabiximols  
More Chemistry

Pharmacology

Alternative names

gw1000 | gw 1000 | gw-1000 | gw-1000-02 | nabiximols | sativex | tetrahydrocannabinol-cannabidiol combination

Organizations (30)

Research & Development (30)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (25)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (25)


 

Cannabis (Phase 1)

Cerebral Palsy (Phase 3)

Diabetic Neuropathies (Phase 3)

Drugs, Investigational (Phase 1)

Healthy Volunteers (Phase 1)

Kidney Diseases (Phase 1)

Liver Diseases (Phase 1)

Magnetic Resonance Imaging (Phase 1)

Marijuana Abuse (Phase 2)

Multiple Sclerosis (Phase 4)

Muscle Spasticity (Phase 4)

Neoplasms (Phase 3)

Neuralgia (Phase 3)

Pain (Phase 3)

Palliative Care (Phase 3)

Peripheral Nervous System Diseases (Phase 3)

Pharmacokinetics (Phase 1)

Pharmacology (Phase 1)

Renal Insufficiency (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 1)

Stress Disorders, Post-Traumatic (Phase 2/Phase 3)

Substance Abuse, Oral (Phase 1)

Tic Disorders (Phase 3)

Tourette Syndrome (Phase 3)

Urinary Bladder (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 55
  • # of Trial Organizations: 30

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue